LENZ Therapeutics (NASDAQ:LENZ) Stock Price Up 6.8% – What’s Next?

LENZ Therapeutics, Inc. (NASDAQ:LENZ) shot up 6.8% on Monday . The company traded as high as $37.93 and last traded at $37.93. 9,322 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 136,030 shares. The stock had previously closed at $35.50.

Wall Street Analyst Weigh In

Several analysts recently issued reports on LENZ shares. HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of LENZ Therapeutics in a report on Thursday, November 7th. Raymond James initiated coverage on LENZ Therapeutics in a research note on Friday, September 27th. They set an “outperform” rating and a $37.00 price target for the company. William Blair raised LENZ Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Piper Sandler restated an “overweight” rating and issued a $36.00 price objective on shares of LENZ Therapeutics in a report on Thursday, August 15th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $35.40.

LENZ Therapeutics Trading Up 1.0 %

The company has a fifty day simple moving average of $27.89 and a two-hundred day simple moving average of $22.88.

LENZ Therapeutics (NASDAQ:LENZ) last posted its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.09. During the same period last year, the business earned ($1.33) earnings per share. On average, equities research analysts anticipate that LENZ Therapeutics, Inc. will post -2.09 EPS for the current year.

Institutional Trading of LENZ Therapeutics

Large investors have recently modified their holdings of the company. American International Group Inc. acquired a new position in LENZ Therapeutics during the 1st quarter worth $44,000. SG Americas Securities LLC bought a new position in shares of LENZ Therapeutics in the third quarter worth about $107,000. MetLife Investment Management LLC acquired a new position in shares of LENZ Therapeutics during the 3rd quarter worth about $182,000. GSA Capital Partners LLP bought a new stake in LENZ Therapeutics during the 3rd quarter valued at approximately $246,000. Finally, Squarepoint Ops LLC acquired a new stake in LENZ Therapeutics in the 2nd quarter valued at approximately $181,000. 54.32% of the stock is owned by institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.